[Biologic effects of high doses per fraction].

Effets biologiques des hautes doses par fraction.

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 06 06 2019
revised: 18 06 2019
accepted: 19 06 2019
pubmed: 25 2 2020
medline: 14 5 2020
entrez: 25 2 2020
Statut: ppublish

Résumé

The radiobiological concepts described for conventional doses per fraction (1.8 to 2Gy) seem difficult to translate to high doses per fraction radiobiology. In fact, specific mechanisms are involved during high dose per fraction irradiation, involving vascular microenvironment damage and anti tumor immune response. The "5R's" of "classical" radiobiology (factors influencing the response of healthy or cancer cells to irradiation) seem to play a less important role in case of high doses per fraction. In addition, applicability of the linear quadratic model in this context is debated. It is therefore difficult to obtain reliable equivalent doses, hence the importance of including our patients in clinical trials, especially in case of concomitant systemic treatments. In addition to stereotactic radiotherapy, flash irradiations defined by a dose rate approximately 2000 times faster than "conventional" irradiation can also deliver high doses per fraction, with a much better tolerance for normal tissue without loss of anti tumor efficacy. Finally, availability of robust prospective data is a prerequisite to answer the question of short and long-term risk/benefit ratio of these different irradiation techniques.

Identifiants

pubmed: 32089502
pii: S1278-3218(20)30012-3
doi: 10.1016/j.canrad.2019.06.017
pii:
doi:

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

153-158

Informations de copyright

Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Auteurs

N Grellier (N)

Service d'oncologie-radiothérapie, hôpitaux universitaires Henri-Mondor, CHU de Henri-Mondor, université Paris-Est-Créteil, AP-HP, 51, avenue Mal-De-Lattre-de-Tassigny, 94000 Créteil, France. Electronic address: noemie.grellier@aphp.fr.

Y Belkacemi (Y)

Service d'oncologie-radiothérapie, hôpitaux universitaires Henri-Mondor, CHU de Henri-Mondor, université Paris-Est-Créteil, AP-HP, 51, avenue Mal-De-Lattre-de-Tassigny, 94000 Créteil, France; Inserm, unité 955 équipe 07, Créteil, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH